Attenuation of transplant arteriosclerosis by oral feeding of major histocompatibility complex encoding chitosan-DNA nanoparticles.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Transplant Immunology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.trim.2012.11.007PMID 23220147
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral Gene Application Using Chitosan-DNA Nanoparticles Induces Transferable Tolerance

  2012cited by this paper
• Oral tolerance

  2011cited by this paper
• Induction of oral tolerance to peanut: a successful home-based protocol.

  2010cited by this paper
• Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery

  2010cited by this paper
• Efficacy of the slow dose-up method for specific oral tolerance induction in children with cow's milk allergy: comparison with reported protocols.

  2010cited by this paper
• A novel recombinant peptide containing only two T-cell tolerance epitopes of chicken type II collagen that suppresses collagen-induced arthritis.

  2009cited by this paper
• A pilot study on the immunological effects of oral administration of donor major histocompatibility complex class II peptides in renal transplant recipients

  2008cited by this paper
• In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance.

  2007cited by this paper
• Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.

  2007cited by this paper
• Regulation of Transplant Arteriosclerosis by CD25+CD4+ T Cells Generated to Alloantigen In Vivo

  2007cited by this paper
• Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis.

  2007cited by this paper
• Oral tolerance

  2005cited by this paper
• Intrathymic delivery of plasmid-encoding endoplasmic reticulum signal-sequence-deleted MHC class I alloantigen can induce long-term allograft survival

  2004cited by this paper
• Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment.

  2004cited by this paper
• Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells.

  2004cited by this paper
• Chitosan Nanoparticles for Plasmid DNA Delivery: Effect of Chitosan Molecular Structure on Formulation and Release Characteristics

  2004cited by this paper
• Recent advances on chitosan-based micro- and nanoparticles in drug delivery.

  2004cited by this paper
• Vaccination with Plasmid DNA Activates Dendritic Cells via Toll-Like Receptor 9 (TLR9) but Functions in TLR9-Deficient Mice 1

  2003cited by this paper
• Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes

  2003cited by this paper
• Syngeneic bone marrow transduced with a recombinant retroviral vector to express endoplasmic reticulum signal-sequence-deleted major histocompatibility complex class-I alloantigen can induce specific immunologic unresponsiveness in vivo

  2003cited by this paper
• Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/interleukin-10 and suppression of experimental autoimmune encephalomyelitis.

  2003cited by this paper
• CD25+CD4+ Regulatory T Cells Prevent Graft Rejection: CTLA-4- and IL-10-Dependent Immunoregulation of Alloresponses1

  2002cited by this paper
• Linked unresponsiveness: early cytokine gene expression profiles in cardiac allografts following pretreatment of recipients with bone marrow cells expressing donor MHC alloantigen.

  2002cited by this paper
• Control of rheumatoid arthritis by oral tolerance.

  2001cited by this paper
• Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells.

  2001cited by this paper
• Alloantigen-induced specific immunological unresponsiveness.

  2001cited by this paper
• Oral feeding of an immunodominant MHC donor‐derived synthetic class I peptide prolongs graft survival of heterotopic cardiac allografts in a high‐responder rat strain combination

  2000cited by this paper
• Oral insulin administration and residual (β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial

  2000cited by this paper
• Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

  2000cited by this paper
• NONDEPLETING ANTI-CD4 MONOCLONAL ANTIBODY ENHANCES THE ABILITY OF ORAL ALLOANTIGEN DELIVERY TO INDUCE INDEFINITE SURVIVAL OF CARDIAC ALLOGRAFTS: ORAL TOLERANCE TO ALLOANTIGEN1

  2000cited by this paper
• Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy

  1999cited by this paper
• Pretransplant administration of a single donor class I major histocompatibility complex molecule is sufficient for the indefinite survival of fully allogeneic cardiac allografts: evidence for linked epitope suppression.

  1997cited by this paper
• Intervention in autoimmune diabetes by targeting the gut immune system.

  1997cited by this paper
• Development of a mouse aortic transplant model of chronic rejection

  1995cited by this paper
• Induction of anergy or active suppression following oral tolerance is determined by antigen dosage.

  1994cited by this paper
• Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

  1993cited by this paper
• Effects of oral administration of type II collagen on rheumatoid arthritis.

  1993cited by this paper
• Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation.

  1993cited by this paper
• INDUCTION OF TRANSPLANTATION TOLERANCE IN ADULTS USING DONOR ANTIGEN AND ANTI‐CD4 MONOCLONAL ANTIBODY

  1992cited by this paper

• Genetically modified cell membrane proteins in tissue engineering and regenerative medicine

  2025cites this paper
• Cationic nanoparticles-based approaches for immune tolerance induction in vivo.

  2023cites this paper
• Polymer nanotherapeutics to correct autoimmunity.

  2022cites this paper
• Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases.

  2015cites this paper
• Immunosuppressive nano-therapeutic micelles downregulate endothelial cell inflammation and immunogenicity.

  2015cites this paper
• From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity

  2015cites this paper
• Lung transplantation: Transplant outcomes, graft dysfunction

  year unknowncites this paper